Natural history of familial cavernous malformations: CCM study
Part of Brain & nervous system, Genetic & congenital clinical trials.
This study follows people with a hereditary form of cavernous malformations (clusters of abnormal blood vessels in the brain). It aims to understand how the condition changes over time, without testing any new treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have familial cerebral cavernous malformations (FCCM) confirmed by a genetic test showing a change in the CCM1, CCM2, or CCM3 gene.
- You may have had symptoms like brain bleeds, strokes, seizures, or other neurological problems, or you may have no symptoms at all.
- You must be expected to live at least as long as the study lasts.
- You or your guardian must sign a form agreeing to take part.
- You cannot have a pacemaker or any other condition that would make an MRI scan unsafe.
- You cannot be in another interventional study, and you must be able to cooperate with the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how to best treat people with untreated cerebral cavernous malformations (a cluster of abnormal blood vessels in the brain). It compares outcomes between those who have surgery and those who are monitored with regular check-ups, and will follow participants for a long time to see how they do.
This study uses special MRI scans to measure brain changes in people whose seizures are related to one cerebral cavernous malformation (a type of abnormal blood vessel in the brain). It aims to find a measurable “biomarker” from MRI that may help understand the epilepsy and the brain structure around it.
This trial tests if daratumumab can help people with inherited cavernous malformations (clusters of abnormal blood vessels in the brain) who have had symptoms like bleeding or seizures. It aims to see if the drug is safe and might reduce future problems.
This study collects blood samples and medical information from people with rare inherited blood vessel diseases of the brain, and from healthy volunteers. Researchers use this information to understand these diseases better and develop future treatments.
This study looks at brain MRI scans in people with cerebral amyloid angiopathy (a condition where amyloid builds up in brain blood vessels). The goal is to search for “biomarkers,” or measurable scan features, to better understand and detect the disease in some people before symptoms or during symptoms.
This study looks at how brain arteriovenous malformations (abnormal connections between arteries and veins in the brain) behave over time, and how different treatment choices affect outcomes. It may help researchers better predict prognosis and guide future care.
Hear when a new CCM trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.